2 Dec 2022 , 01:34 AM
Zydus Lifesciences US subsidiary Zydus Pharmaceuticals USA Inc has received tentative approval from the United States Food and Drug Administration USFDA to market Levothyroxine Sodium for injection 100 mcgvial 200 mcgvial and 500 mcgvial USRLD Levothyroxine Sodium injection manufactured by Fresenius Kabi USA LLC
Levothyroxine Sodium injection is indicated for the treatment of myxedema coma Levothyroxine Sodium injection had annual sales of USD 452 mn in the United States according to IQVIA data IQVIA MAT Sep 2022
The drug will be manufactured at the groups injectable manufacturing facility at Jarod near Vadodara India
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
